Argenica Therapeutics Ltd ( (AU:AGN) ) has issued an update.
Argenica Therapeutics has completed dosing the last patient in its Phase 2 clinical trial for ARG-007, a treatment aimed at reducing brain injury in acute ischaemic stroke patients. The trial, which involved 92 patients, will remain blinded until the final assessments are completed, with topline data expected in Q3 2025. This milestone underscores the company’s rapid progress in clinical development and highlights Australia’s strong capabilities in stroke research, potentially enhancing Argenica’s position in the biotechnology industry.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following stroke and other neurological conditions. Their lead candidate, ARG-007, has shown promise in pre-clinical models for stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. The company is currently conducting a Phase 2 clinical trial in ischaemic stroke patients while also generating preclinical data for other neurological conditions.
YTD Price Performance: 4.76%
Average Trading Volume: 139,631
Technical Sentiment Signal: Buy
See more insights into AGN stock on TipRanks’ Stock Analysis page.